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 The term antidepressant refers to a drug that helps to rectify speciﬁ c biological abnormalities 
that give rise to the symptoms of 
depression. This exempliﬁ es what 
we have called the “disease-centred” 
model of psychotropic drug action [1]. 
Modelled on paradigmatic situations 
in general medicine—such as the use 
of insulin in diabetes, antibiotics in 
infectious disease, chemotherapy in 
cancer—the disease-centred model 
suggests that antidepressants help 
restore normal functioning by acting 
on the neuropathology of depression 
or of depressive symptoms. 
 In contrast, we propose in this Essay 
that an alternative “drug-centred” 
model can better explain observed 
drug effects in psychiatric conditions. 
This drug-centred model suggests that 
instead of relieving a hypothetical 
biochemical abnormality, drugs 
themselves cause abnormal states, 
which may coincidentally relieve 
psychiatric symptoms (Table 1). 
Alcohol’s disinhibiting effects may 
relieve symptoms of social phobia, 
but that does not imply that alcohol 
corrects a chemical imbalance 
underlying social phobia. Sedation 
may lessen high arousal, present in 
many acute psychiatric situations. 
Drugs that induce indifference, such 
as neuroleptics or opiates, may help 
reduce the distress of acute psychotic 
symptoms. Low-dose stimulants 
may help improve attention and 
concentration in the short term. 
 The disease-centred model in 
psychiatry leads researchers to infer 
antidepressant effects from patients’ 
scores on symptom rating scales 
presumed to assess the manifestations 
of the disease. The drug-centred 
model, on the other hand, suggests 
that physiological and subjective effects 
of drugs should be examined in their 
own right. These effects include various 
forms of sedation, stimulation, and a 
plethora of biopsychological states. 
Depending on individual inclination 
and context (including a person’s 
emotional state upon drug ingestion), 
intoxication with some drugs 
produces euphoria or mood elevation. 
Because tolerance develops, however, 
euphoriant effects do not persist with 
long-term use. If antidepressants or 
any other psychotropic drugs could 
be shown to have mood-elevating 
effects that were long-term and not 
diminished by being in a depressed 
emotional state, this would distinguish 
them from psychotropic drugs that 
cause euphoria and might prove 
uniquely useful in depressed patients 
(see Sidebar). 
 Evaluation of Alternative Models
 The disease-based approach in 
psychiatry has rarely been tested 
directly. Prior to the dominance of 
this approach, which began in the 
1960s, a drug-based model was mostly 
employed [1]. A disease-based model 
could be considered established 
if (1) the pathology of psychiatric 
conditions or symptoms had been 
delineated independently from the 
characterisation of drug action, and 
drug action could be extrapolated from 
that pathology; (2) rating scales used 
to evaluate drug treatment in clinical 
trials reliably detected changes in the 
manifestations of an underlying disease 
process rather than detecting drug-
induced effects; (3) animal models 
of psychiatric conditions selected 
speciﬁ c drugs; (4) drugs thought 
to have a speciﬁ c action in certain 
conditions were shown to be superior 
to drugs thought to have nonspeciﬁ c 
effects; (5) healthy volunteers showed 
different or absent patterns of effects, 
compared with diagnosed patients, 
since drugs would be expected to 
exert their therapeutic effects only 
in an abnormal nervous system 
[2]; and (6) the widespread use of 
supposedly disease-speciﬁ c drugs led to 
demonstrable improvements in short- 
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 Article Summary
 Antidepressants are assumed to 
work on the speciﬁ c neurobiology of 
depressive disorders according to a 
“disease-centred” model of drug action. 
However, little evidence supports this 
idea. An alternative, “drug-centred,” 
model suggests that psychotropic 
drugs create abnormal states that may 
coincidentally relieve symptoms. Drug-
induced effects of antidepressants vary 
widely according to their chemical 
class—from sedation and cognitive 
impairment to mild stimulation and 
occasionally frank agitation. Results 
of clinical trials may be explained by 
drug-induced effects and placebo 
ampliﬁ cation. No evidence shows that 
antidepressants or any other drugs 
produce long-term elevation of mood or 
other effects that are particularly useful 
in treating depression. (See Text S1 for 
French translation.) 
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or long-term outcome of psychiatric 
disorders. Conversely, the absence of 
such evidence could indicate that a 
drug-centred model is preferable to 
guide scientiﬁ c inquiry and produce 
therapeutic advances. 
 Evidence for Disease-Based Action 
of Antidepressants
 The pathology of depression—
the monoamine hypothesis. 
Antidepressants are believed to exert 
their therapeutic effects by acting on 
brain monoamines, which are believed 
to be important determinants of mood. 
However, in a circular chain of logic, 
the monoamine theory of depression 
was itself formulated primarily in 
response to observations that early 
antidepressants increased brain 
monoamine levels [3].
 Independent evidence has not 
conﬁ rmed that there is a monoamine 
abnormality in depression. For 
example, the ﬁ ndings of brain imaging 
studies of serotonin abnormality are 
contradictory. Some found reduced 
serotonin 1A receptor binding in 
drug-free patients who were depressed, 
consistent with the hypothesis that 
selective serotonin reuptake inhibitors 
(SSRIs) improve depression by 
correcting a deﬁ ciency of serotonin 
activity [4,5]. Other studies, however, 
have found no difference between 
patients who are drug-free and controls 
[6,7] or increased binding potential in 
depressed patients [7,8]. Postmortem 
ﬁ ndings of receptor changes in the 
brains of people who committed 
suicide have also been inconsistent 
[9–11]. In some studies, with patients 
who had recovered from depression, 
a tryptophan depletion challenge led 
to a transient increase in depressive 
symptoms. However, these results 
have not been conﬁ rmed in volunteer 
studies [12], and the effect appears to 
be dependent on previous SSRI use 
[13]. Research on catecholamines 
(noradrenaline and adrenalin) is 
similarly confusing and inconclusive 
[14]. 
 Depression rating scales. These scales 
contain items that are not speciﬁ c 
to depression, including sleeping 
difﬁ culties, anxiety, agitation, and 
somatic complaints. These symptoms 
are likely to respond to the nonspeciﬁ c 
sedative effects that occur with most 
tricyclic antidepressants (TCAs) and 
some other antidepressants. Hence, 
changes in rating scale scores may 
merely reﬂ ect drug-induced effects.
 Animal models of depression. 
These models, which usually 
involve biochemical or behavioural 
processes thought to mimic aspects of 
depression in humans, do not select 
antidepressants reliably but produce 
numerous “false positives” with other 
drugs, including stimulants, opiates, 
and neuroleptics. They also produce 
some “false negatives” with supposed 
antidepressant drugs [15]. 
 Antidepressants versus other drugs. 
Many drugs not normally considered 
to be antidepressants show comparable 
effects to antidepressants when given 
to patients who are depressed in some 
randomised controlled trials (RCTs) 
[1,16]. These include benzodiazepines 
[17], opiates [18], buspirone [19], 
stimulants [20], reserpine, and other 
antipsychotics [21].
 Healthy volunteer studies. The fact 
that antidepressants do not appear to 
elevate mood in healthy volunteers 
[22–26] might suggest that they have 
a disease-speciﬁ c action. However, 
because of the nature of depression 
rating scales (as explained above), 
it is unclear that antidepressants 
speciﬁ cally affect mood in patients who 
are depressed. Any effect they have 
over and above placebo may also be 
attributable to an “ampliﬁ ed” placebo 
response (see below). Although 
there are some reports of improved 
sleep in patients with depression who 
are given SSRIs versus volunteers’ 
reports of decreased sleep when given 
SSRIs [27], in general, side effects 
in patient studies are consistent with 
effects on volunteers. For example, 
TCAs show sedation and cognitive 
impairment [28,29], while SSRIs show 
gastrointestinal upset and drowsiness, 
both in patients and in healthy 
volunteers [22]. 
 Outcome of depression. There 
is little evidence outside RCTs that 
the long- or short-term outcome 
of depression is changing as a 
consequence of antidepressant 
use. Recent sharp increases in 
antidepressant use have been 
accompanied by increased prevalence 
and duration of depressive episodes 
[30] and rising levels of sickness 
absence [31]. Naturalistic studies have 
also shown that depressive episodes 
are more frequent and last longer 
among antidepressant users than 
among nonusers [30] and that sickness 
absence is more prolonged [32], 
although severity is likely to explain 
some of this effect (i.e., it is likely that 
patients are on antidepressant drugs 
because they have more severe disease). 
Follow-up studies of people treated 
for depression indicate high levels of 
nonrecovery or relapse [33–35].
 What Do Antidepressants Actually 
Do?
 Since antidepressants come from a 
number of different chemical classes, 
they would be expected to produce 
different sorts of effects. 
 Most TCAs are strongly 
sedative and impair cognitive 
and motor performance [28,29]. 
Amitriptyline causes profound 
electroencephalograph slowing similar 
to chlorpromazine [29]. Trazodone, 
mianserin, and mirtazapine also cause 
sedation and cognitive impairment 
[36,37]. Research on SSRIs has found 
a “lack of profound effects in healthy 
subjects” (p. 17 of [22]). Studies with 
volunteers taking single doses show 
increased attention-test performance 
and motor speed, as well as sleep 
impairment, suggesting a slight 
stimulating effect [22,27]. Studies with 
volunteers who have taken multiple 
doses over days or weeks show either 
no difference from placebo [37,38] 
or impaired concentration, vigilance, 
and memory, and reports of drowsiness 
[22,25,39–41] compared with placebo, 
suggesting that SSRIs have mild 
sedative effects. Patient studies suggest 
 Table 1.  Main Assumptions of Two Models of Psychotropic Drug Action  
Disease-Centred Model Drug-Centred Model
Drugs correct an abnormal brain state Drugs create an abnormal brain state
Therapeutic effects are derived from presumed 
disease pathology 
Therapeutic effects are coincidental and depend 
on social context 
Effects differ between patients and volunteers Effects do not differ between patients and volunteers
Paradigm: insulin for diabetes Paradigm: alcohol for social anxiety
 DOI: 10.1371/journal.pmed.0030240.t001 
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that SSRIs may sometimes cause 
extreme and unpleasant activation or 
agitation [42–44], which can resemble 
neuroleptic-induced akathisia [45]. 
More commonly, SSRIs also cause 
subjective drowsiness or sedation [43]. 
It is therefore difﬁ cult to characterise 
overall effects of SSRIs, which may 
have simultaneous mild stimulant and 
sedating effects. Reboxetine appeared 
to be subjectively mildly stimulant or 
“energy enhancing” in one volunteer 
study [25].
 In volunteer studies, measures of 
mood speciﬁ cally address subjective 
feelings and show either no effects 
after antidepressant administration 
or dysphoria [22–26]. Two volunteer 
studies found slightly improved 
recognition of positive emotional 
material and reduced recognition of 
negative emotional states compared 
with placebo [23,24]. Another found 
reduced reaction to negative events 
[26]. However, without a comparison 
with other drugs, one cannot know 
whether these are speciﬁ c effects of 
the antidepressants tested, or simply 
consequences of an intoxicated 
state. Possibly, some antidepressants 
share the opiates’ and neuroleptics’ 
particular emotional blunting effects. 
Alternatively, drug-induced states 
may nonspeciﬁ cally reduce emotional 
sensitivity. 
 Drug Effects in Clinical Trials
 RCTs of antidepressants report that 
drug-treated trial participants show 
greater improvement on rating 
scale scores than placebo-treated 
participants. However, this difference 
was shown to be small in recent meta-
analyses—about two points on the 
Hamilton Rating Scale for Depression, 
or small differences in improvement 
rates [46,47]. Drug-induced effects 
could account for this difference in 
several ways. In the Hamilton Rating 
Scale for Depression, for example, 
three items on sleep, two on anxiety 
and one on agitation can score up 
to 16 points (a total score between 
19–22 on the Hamilton Rating Scale 
for Depression indicates severe 
depression). On these items, any drug 
with sedative effects would be likely to 
outperform placebo.
 In addition, because inert placebos 
create nowhere near the range and 
intensity of effects (including side 
effects) that active drugs produce, 
RCTs of psychotropic drugs that use 
inert placebos (rather than active 
placebos, which mimic side effects 
of drugs) are not truly blinded [48]. 
In that case, outcomes for people on 
antidepressants are likely to be subject 
to ampliﬁ ed expectations compared 
with those on inert placebo [48]. This 
“placebo ampliﬁ cation” might be 
exacerbated in people who have taken 
antidepressants before and have not 
responded negatively [49]; modern 
trials are likely to select such patients 
above others [50,51]. 
 Therefore, RCT evidence cannot 
conﬁ rm that antidepressants have 
a speciﬁ c mood-elevating effect 
in patients. This is consistent with 
evidence that they have no mood-
elevating effect in volunteers. Drugs 
known to produce short-term 
euphoria require an increasing dose 
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 Alcohol can relieve symptoms of social phobia, but this does not mean that alcohol 
corrects a chemical imbalance underlying social phobia
 (Photo: J Troha/National Cancer Institute) 
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to maintain this effect (tolerance) and 
are associated with a compensatory 
dysphoria on discontinuation. Drugs 
such as antipsychotics cause dysphoria 
and some depressive symptoms [52]. 
So far, however, there is no compelling 
evidence that there exists any drug-
induced effect consisting of a sustained 
elevation of mood.
 Clinical and Theoretical 
Implications
 The idea that antidepressant drugs 
target a speciﬁ c biological state that 
produces depression strongly justiﬁ es 
the disease model of depression and 
its medical treatment [53]. Therefore, 
abandoning the disease-centred model 
of antidepressant action squarely 
challenges the notion of depression as 
a biologically based medical disease. 
The argument presented here supports 
claims that the medical concept of 
depression obscures the diversity of 
problems and experiences that come 
to be so labelled, and that social 
explanations and interventions have 
been undervalued [54,55]. By contrast, 
a drug-centred model allows drug 
treatment to be considered without 
necessarily accepting a disease model. 
 A drug-centred model suggests that 
drug effects cannot easily be parcelled 
into “therapeutic” and “adverse” 
effects, since the same effect may have 
desirable and undesirable implications. 
Neuroleptic-induced indifference and 
sedation may help in acute psychosis 
but may impede long-term recovery. 
Increased passivity shown by a child on 
stimulants might help in a structured 
classroom but not in a summer camp. 
Drug use is always a ﬁ ne balancing 
act, and patients’ experiences are 
of primary importance in deciding 
whether there is more to be gained 
than lost. Such decisions require 
patients and professionals to cooperate 
to explore precisely what patients hope 
to achieve with drugs, matching these 
aims to known drug-induced effects.
 Taking a drug-centred approach 
to the treatment of depression, we 
would conclude that no presently 
known effects of any drugs, including 
antidepressants, are likely to do more 
good than harm in the long term. 
In the short term, sedative effects 
of drugs may help people who are 
acutely anxious, highly aroused, or 
have difﬁ culty sleeping. The common 
practice of prescribing short-term, 
low-dose sedative TCAs, for which 
general practitioners have frequently 
been criticised, may therefore be a 
rational one. Similarly, short-term 
benzodiazepine prescribing may 
occasionally be justiﬁ ed, bearing in 
mind the problem of dependency. 
On the other hand, although several 
drug classes (and possibly some 
antidepressants) are known to induce 
psychic indifference, the utility and 
desirability of this effect is doubtful.
 Conclusion
 Many patients are led to believe, by 
their physicians and by advertising, 
that antidepressant drugs will act on 
the biological cause of their depressed 
state by rectifying a “chemical 
imbalance” [56]. On the contrary, 
our analysis indicates that there are 
no speciﬁ c antidepressant drugs, 
that most of the short-term effects of 
antidepressants are shared by many 
other drugs, and that long-term 
drug treatment with antidepressants 
or any other drugs has not been 
shown to lead to long-term elevation 
of mood. We suggest that the term 
“antidepressant” should be abandoned. 
We have proposed an alternative 
drug-centred model of drug action 
that is consistent with a demedicalised 
approach to depression.  
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 Text S1. Translation of Article Summary 
into French by David Cohen
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